The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502) plasma-derived therapy Gammagard Liquid, a human immune globulin, for use as induction therapy and treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. This decision is supported by clinical data demonstrating that the intravenous immunoglobulin (IVIG) improved functional disability in 94.4% of study participants.
As stated in the press release, Gammagard Liquid is also approved in the US for the treatment of primary immunodeficiency and the neuromuscular disorder known as multifocal motor neuropathy.- Flcube.com
